Eight years of experience with vismodegib for advanced and multiple basal cell carcinoma patients in the Netherlands: a retrospective cohort study.

ABSTRACT:

Background

Vismodegib has been used for the treatment of locally advanced basal cell carcinoma (laBCC) and metastatic BCC (mBCC) since 2011. Most efficacy and safety data are provided by clinical trials. This study evaluates the effectiveness of vismodegib for the treatment of laBCC, mBCC and basal cell nevus syndrome (BCNS) patients, and the tumour characteristics associated with a higher probability of achieving a complete response in the Netherlands.

Methods

A retrospective cohort study that included all patients ≥18 years with histologically proven basal cell carcinoma that received ≥1 dose of vismodegib between July 2011 and September 2019 in the Netherlands.

Results

In total, 48 laBCC, 11 mBCC and 19 BCNS patients were included. Median progression-free survival

SUBMITTER: Verkouteren BJA 

PROVIDER: S-EPMC8007568 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature